MichaelJKozalMD

Infectious Disease • Palo Alto, CA

Professor & Senior Associate Dean for Veteran Affairs, Stanford University School of Medicine; Chief of Staff, VA Palo Alto Healthcare System

Join to view full profile

Dr. Kozal is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kozal's full profile

Already have an account?

Office
3801 Miranda Ave
Palo Alto, CA 94304
Phone+1 650-374-9610

Education & Training

Stanford Health Care-Sponsored Stanford UniversityFellowship, Infectious Disease, 1991 - 1994
University of Nebraska Medical Center College of MedicineResidency, Internal Medicine, 1988 - 1991
University of Nebraska College of MedicineClass of 1988

Certifications & Licensure

NE State Medical License 1990 - 2026
CA State Medical License 1991 - 2025
CT State Medical License 2000 - 2025
TX State Medical License 1999 - 2025
IA State Medical License 1995 - 2000
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Infectious Disease

Clinical Trials

Pilot Study of a Raltegravir Based NRTI Sparing Regimen Start of enrollment: 2009 May 01
Completed
Not Applicable
Collection of Samples From HIV-1 Infected Individuals for Evaluation of the Aptima HIV-1 Assay Start of enrollment: 2014 Jan 01
Completed
Evaluation of the HSV 1 & 2 Assay in Specimens From Symptomatic Subjects Start of enrollment: 2014 Dec 01
Completed
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients Start of enrollment: 2015 Feb 23
Active, not recruiting
Phase 3
Dose-finding Study of BMS-955176 to Treat HIV-1 Infected Treatment-naive Adults Start of enrollment: 2015 May 12
Terminated
Phase 2
Ibalizumab Plus Optimized Background Regimen in Patient With Multi-Drug Resistant HIV Start of enrollment: 2015 Aug 01
Completed
Phase 3
Ibalizumab Plus Optimized Background Regimen in Treatment-Experienced Patients With Multi-Drug Resistant HIV-1 Start of enrollment: 2016 Mar 01
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

Rate of response to initial antiretroviral therapy according to level of pre-existing HIV-1 drug resistance detected by next-generation sequencing in the strategic tim...
Alessandro Cozzi-Lepri, David Dunn, Anna Tostevin, Rasmus L Marvig, Marc Bennedbaek
HIV Medicine. 2024-02-01
11 citations
Week 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHTE Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1.
Margaret Gartland, Pedro Cahn, Edwin DeJesus, Ricardo Sobhie Diaz, Robert Grossberg
Antimicrobial Agents and Chemotherapy. 2022-06-21
7 citations
Evaluation of HIV-1 reservoir size and broadly neutralizing antibodies (bNAb) susceptibility in acute ART treated individuals.
Brian Moldt, Huldrych F. Günthard, Kimberly A. Workowski, Susan J. Little, Joseph J. Eron
AIDS. 2021-09-29

Journal Articles

Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection
Michael Kozal, Edwin Dejesus, Cyril Llamoso, The New England Journal of Medicine

Other

Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection
Michael Kozal, MD, The New England Journal of Medicine
https://www.doximity.com/articles/53c3f551-51dc-4278-9eda-95049ceeac02
UpToDate, Wolters Kluwer Health - 2012-12-06
Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection
Michael Kozal, MD, New England Journal of Medicine
https://www.doximity.com/articles/53c3f551-51dc-4278-9eda-95049ceeac02
UpToDate, Wolters Kluwer Health - 2013-02-19

Press Mentions

Federman Named Chief of Medicine, Vice Chair for Veterans AffairsJanuary 12th, 2021